Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Seattle Genetics Inc patents


Recent patent applications related to Seattle Genetics Inc. Seattle Genetics Inc is listed as an Agent/Assignee. Note: Seattle Genetics Inc may have other listings under different names/spellings. We're not affiliated with Seattle Genetics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Seattle Genetics Inc-related inventors


Cd19 binding agents and uses thereof

... Seattle Genetics Inc

Humanized anti-cd70 binding agents and uses thereof

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological... Seattle Genetics Inc

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.... Seattle Genetics Inc

Anti-ntb-a antibodies and related compositions and methods

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing... Seattle Genetics Inc

Methods for screening antibodies

The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.... Seattle Genetics Inc

Pyrrolobenzodiazepines and targeted conjugates

This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in... Seattle Genetics Inc

Pyrrolobenzodiazepines and targeted conjugates

(c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.... Seattle Genetics Inc

Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30... Seattle Genetics Inc

Targeted delivery of tertiary amine-containing drug substances

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using... Seattle Genetics Inc

Cyclodextrin and antibody-drug conjugate formulations

Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.... Seattle Genetics Inc

Bcma antibodies and use of same to treat cancer and immunological disorders

The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.... Seattle Genetics Inc

Hydrophilic antibody-drug conjugates

Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.... Seattle Genetics Inc

Cd33 antibodies and use of same to treat cancer

The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.... Seattle Genetics Inc

Beta-glucuronide-linker drug conjugates

Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.... Seattle Genetics Inc

Optimal dosing of a cd19-antibody drug conjugate

Methods of optimal dosing of CD19-antibody drug conjugates are disclosed.... Seattle Genetics Inc

Preparing antibodies from cho cell cultures for conjugation

The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are... Seattle Genetics Inc

Targeted pyrrolobenzodiazapine conjugates

Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.... Seattle Genetics Inc

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.... Seattle Genetics Inc

Methods of inhibition of protein fucosylation in vivo using fucose analogs

The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.... Seattle Genetics Inc

Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

This disclosure provides optimized formulations for CD19 antibodies and antibody-drug conjugates (ADCs)... Seattle Genetics Inc

Humanized anti-cd70 binding agents and uses thereof

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological... Seattle Genetics Inc

Monomethylvaline compounds capable of conjugation to ligands

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.... Seattle Genetics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Seattle Genetics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Seattle Genetics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###